Concern over COVID-19 stems not only from its high degree of virulence, but from its ability to continuously mutate and produce new variants. An effective vaccine can help slow the virus’ spread, but the question of how to deal with its continuous mutations is key.
Mass production of the most well-known novel coronavirus vaccines in production, including by AstraZeneca PLC, Moderna Inc and Pfizer Inc, has a high technological threshold, especially for those using messenger RNA (mRNA) technology, since manufacturers need to overcome the challenges of storage and transportation at ultra-low temperatures.
Founded in 2018, Ascendo Biotechnology Inc (先知生技) has a research and development team with 30 years of clinical drug research experience, focused on immune-related drug research.
Photo courtesy of Ascendo Biotechnology Inc
Using quantum mechanics technologies, Ascendo has developed a proprietary NanoCherubTM electric-kinetic nanocomplex antigen adjuvant and delivery platform, designed to rapidly respond to mutations without the challenges of ultra-low temperature storage and transportation, and to produce large quantities of vaccines quickly
‧ NanoCherubTM in the fight against COVID-19
Doctors and scientists have been racking their brains for a solution to the constantly mutating virus. Using quantum mechanics calculations, Ascendo can produce effective vaccines quickly, with a precise and flexible technology circumventing the need for the constant testing of more traditional approaches.
Last year, Ascendo started working with academic research institutions in Taiwan on developing a COVID-19 vaccine, for the first time using quantum mechanics technology to design a drug delivery system encapsulating antigens to form a positively charged nanocomplex, enabling immune cells to generate a strong and effective response to the NanoCherubTM Electric-Kinetic nanocomplex and achieving a balanced and robust Th1/Th2 immunity.
The ASD254 vaccine developed by Ascendo last year showed excellent results in animal studies using mice, which most closely replicate the symptoms of the novel coronavirus in humans.
All vaccinated animals received 100 percent immune protection when tested with the live virus. Ascendo soon plans to apply to the Food and Drug Administration for phase 1 human trials, hoping to enter mass production next year.
The drug delivery platform can significantly shorten development times and respond to virus mutations, and the NanoCherubTM Electric-Kinetic nanocomplex can consistently induce balanced and strong Th1/Th2 immunity against encapsulated antigens, including full pathogens, subunit proteins, peptides and messenger ribonucleic acid, with the added advantage of the vaccines only needing to be stored at 2°C to 8°C.
‧ Hepatitis B therapeutic vaccine completed in animal efficacy trials
Ascendo has also completed animal efficacy trials for its ASD253 vaccine for chronic hepatitis B. Following preclinical trials, Phase 1 human trials are to begin next year, when ASD253 is expected to become the world’s first vaccine for chronic hepatitis B.
The company also hopes to develop vaccines for HIV (AIDS), dengue fever, Zika and pan-influenza viruses.
Six Taiwanese companies, including contract chipmaker Taiwan Semiconductor Manufacturing Co. (TSMC), made the 2025 Fortune Global 500 list of the world’s largest firms by revenue. In a report published by New York-based Fortune magazine on Tuesday, Hon Hai Precision Industry Co. (better known as Foxconn) ranked highest among Taiwanese firms, placing 28th with revenue of US$213.69 billion. Up 60 spots from last year, TSMC rose 60 places to reach No. 126 with US$90.16 billion in revenue, followed by Quanta Computer Inc. at 348th, Pegatron Corp. at 461st, CPC Corp., Taiwan at 494th and Wistron Corp. at 496th. According to Fortune, the world’s
NEW PRODUCTS: MediaTek plans to roll out new products this quarter, including a flagship mobile phone chip and a GB10 chip that it is codeveloping with Nvidia Corp MediaTek Inc (聯發科) yesterday projected that revenue this quarter would dip by 7 to 13 percent to between NT$130.1 billion and NT$140 billion (US$4.38 billion and US$4.71 billion), compared with NT$150.37 billion last quarter, which it attributed to subdued front-loading demand and unfavorable foreign exchange rates. The Hsinchu-based chip designer said that the forecast factored in the negative effects of an estimated 6 percent appreciation of the New Taiwan dollar against the greenback. “As some demand has been pulled into the first half of the year and resulted in a different quarterly pattern, we expect the third quarter revenue to decline sequentially,”
WEAKER ACTIVITY: The sharpest deterioration was seen in the electronics and optical components sector, with the production index falling 13.2 points to 44.5 Taiwan’s manufacturing sector last month contracted for a second consecutive month, with the purchasing managers’ index (PMI) slipping to 48, reflecting ongoing caution over trade uncertainties, the Chung-Hua Institution for Economic Research (CIER, 中華經濟研究院) said yesterday. The decline reflects growing caution among companies amid uncertainty surrounding US tariffs, semiconductor duties and automotive import levies, and it is also likely linked to fading front-loading activity, CIER president Lien Hsien-ming (連賢明) said. “Some clients have started shifting orders to Southeast Asian countries where tariff regimes are already clear,” Lien told a news conference. Firms across the supply chain are also lowering stock levels to mitigate
DIVERSIFYING: Taiwanese investors are reassessing their preference for US dollar assets and moving toward Europe amid a global shift away from the greenback Taiwanese investors are reassessing their long-held preference for US-dollar assets, shifting their bets to Europe in the latest move by global investors away from the greenback. Taiwanese funds holding European assets have seen an influx of investments recently, pushing their combined value to NT$13.7 billion (US$461 million) as of the end of last month, the highest since 2019, according to data compiled by Bloomberg. Over the first half of this year, Taiwanese investors have also poured NT$14.1 billion into Europe-focused funds based overseas, bringing total assets up to NT$134.8 billion, according to data from the Securities Investment Trust and Consulting Association (SITCA),
RSS